Insights
At Inbeeo, Market Access truly is our passion and we love to share our thoughts on the latest developments in the field through our blog and also in publications. Should you have a topic that you would value our thoughts on then please do get in touch – we would love to hear from you.


France to Adopt a Market Access Pathway Like the German System

Rare Disease Day 2021: UK Roadmap to Improving Care for Rare Disease Patients

Unpacking the biotech sector: What sets this sector apart and what are the challenges

How are payers adapting to the ATMP revolution?

Four Market Access Measures Triggered by COVID-19 That Are Here To Stay
Many market access decisions were intended to provide rapid one-off answers to one of the most extraordinary situations healthcare systems have ever had to face, but some of them are telling us something about the more profound changes that are likely to affect pharmaceutical market access in the longer run.

Reflections on The Initial Impact of COVID-19 on Global Market Access Activities

How Payers in the US & Europe are adapting to the ATMP revolution
So what are ATMPs exactly and why all the fuss about these therapies and the impact they are having within the market? Inbeeo hosted a free to attend webinar looking into this topic focusing on some specific country challenges within the US and EU, with 60+ attendees contributing to the discussion during the Q&A.

Drug R&D Public Funding – The Next Level Of Price Transparency Policies?

Tackling Rising Drug Costs in the US: Is ERP an Option?

4 Take-Away Messages From The Zolgensma® Pricing Storm

Decoding the data: Analytics of Drug Pricing Tweets

Four Definitions of Value-Based Pricing and Counting

In France, the value equation may change (a little)

Six Drugs that Cost a Medicare Part D Beneficiary more than $10,000 a Year
No one will argue that Medicare Part D met a genuine need at its inception in the mid-2000s – offering Medicare beneficiaries an affordable voluntary health insurance plan that would cover their outpatient prescription needs. Fast forward 10 years. Has Part D met its objective? In terms of the availability of a wide range of plans at an affordable premium in all parts of the nation, yes, definitely. In terms of actual payments made to beneficiaries, this is a question mark.

The Dust Never Settled after Drug Pricing 9/22

Why I Prefer a Value-Based Healthcare Mayhem over the Status Quo

Healthcare Appraisal: The Evolution of Value Based Healthcare

Ask Not What Payers Can Do for You – Ask What You Can Do for Payers

Three Reasons Why Value Definition Is The Ultimate Challenge for Pharma

Care Affordability Index or How to Go Beyond the “# of Lives Covered” Metric

Drug Pricing – Feeling the Squeeze

Pharma Payers: Three Things They Want (Beyond Low Prices)
